The Trebol study. Quetiapine in the bordeline personality disorder: Patient's attitude and compliance

Abstract

Introduction:

Nowadays the Borderline Personality Disorder (BPD) lacks any treatment with administrative approval. International prestige guidelines accept the generalized use of atypical antipsychotics by clinicians for this disorder, including quetiapine.

Objective:

To evaluate the clinical effect of Quetiapine in the treatment of BPD and the patient's perception of this treatment.

Method:

Multi-center, naturalistic, retrospective study. Patients over 18 with BPD diagnoses (DSM-IV-TR) in treatment with quetiapine for the previous 6 months were included. Assessments: CGI-C (Clinical Global Impression of Change), DAI-10 (Drug Attitude Inventory, 10 item) and a likert scale measuring the patient's subjective compliance.

Results:

105 patients were included. Mean age was 35.25±9.68 years old. 53.3% were male. Mean dose of Quetiapine was 422.06 mg/day (SD:171.42). The CGI-C results showed that 94.3% of the patients improved along the previous 6 months in treatment with quetiapine; 5,7% had no changes and 0% impaired. According to the DAI-10 results most of the patients thought good things about medication outweighed the bad (82,9%), took medication of their own free choice (72,4%) and associated treatment with breakdowns prevention (75.2%). Regarding to the perception of quetiapine most of the patients felt more relaxed (89.5%), with clearer thoughts (62.9%) and didn't associate treatment with sluggishness (62.9%) or strangeness and doping-up (74.3%). 96.1% of the patients reported compliance over 70%.

Conclusions:

Clinicians found quetiapine effective for treating BPD and most of the patients perceived it positively and showed high levels of compliance